514 Il28b Genotype Is Not Useful for Predicting Treatment Outcome in Asian Chronic Hepatitis B (Chb) Patients Treated With Pegylated-Interferon-a (Pifn)

Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population

“…Similarly, a recent study from Italy showed that IL28B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN (Boglione et al, 2014a). However, Holmes found that there was no association between IL28B genotype and treatment response (serological, virological or biochemical) to PEG-IFN monotherapy in either HBeAg-positive or HBeAg-negative CHB patients (Holmes et al, 2013). Likewise, de Niet et al found no significant association between IL28B polymorphisms and HBsAg seroconversion or HBeAg seroconversion in CHB patients (de Niet et al, 2012).…”

“…Genetic polymorphisms of HLA, CYP27B1, IL28B and IFN-stimulated genes were shown to be related to IFN efficacy in CHB patients (Boglione et al, 2014a(Boglione et al, , 2014bHan et al, 2005;Holmes et al, 2013;King et al, 2002;Lampertico et al, 2013;Sonneveld et al, 2012). However, it is still unclear how host genetic factors affect PEG-IFN efficacy in CHB patients.…”

“…Recent studies suggest that both viral and host factors can influence PEG-IFN efficacy (Buster et al, 2009;Hoofnagle and di Bisceglie, 1997;Sonneveld et al, 2010). Genetic factors may affect PEG-IFN efficacy, including human leukocyte antigen (HLA), eukaryotic translation initiation factor 2A (EIF2A), MX1, IL28B, and CYP27B1, but the results are inconclusive (Boglione et al, 2014a(Boglione et al, , 2014bHan et al, 2005;Holmes et al, 2013;King et al, 2002;Lampertico et al, 2013;Sonneveld et al, 2012).…”

Effect of IL28B genotype on hepatitis B and C virus infection

“…Several retrospective studies yielded conflicting results [49]. While some studies reported higher on-and off-treatment viral and serological response [50][51][52][53][54] in both HBeAg-negative and HBeAg-positive patients, others were not able to reproduce these findings [55][56][57][58]. Table 2 shares an overview of selected published studies on the association of IL28B polymorphism with spontaneous HBsAg-clearance or treatment induced treatment response in patients with chronic HBV infection.…”

Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection

“…Some studies did not find significant relationship between IL-28B SNPs and HBV susceptibility (Da Silva Conde et al, 2014;De Niet et al, 2012;Heidari et al, 2016;Holmes et al, 2013;Kandemir et al, 2013;Kim et al, 2013;Lee et al, 2013;Li et al, 2011;Martin-Carbonero et al, 2012;Martin et al, 2010;Ochi et al, 2011;Seto et al, 2013;Tseng et al, 2011;Zhang et al, 2014a). In contrast, other studies showed some favorable genotypes that can predict virological and serological responses in HBeAg-negative and/or positive patients (Lampertico et al, 2013;Seto et al, 2013;Sonneveld et al, 2012;Wu et al, 2012).…”